What Happens When You Stop Taking Ozempic or Mounjaro?

Stopping a GLP-1 medication like Ozempic (Semaglutide) or Mounjaro (Tirzepatide) typically leads to weight regain — often significant and rapid. This is not a failure of willpower. It is a predictable pharmacological consequence of removing a drug that was actively suppressing appetite and altering gut hormone signaling. Understanding what happens physiologically, and what strategies can mitigate weight regain, is essential for anyone considering stopping or being forced to stop due to cost, supply, or side effects.

The short answer: Most patients regain a substantial portion of lost weight within 12 months of stopping a GLP-1 medication. The STEP 4 trial found that patients who stopped semaglutide 2.4 mg after 20 weeks regained approximately two-thirds of their lost weight within one year. Blood sugar levels in diabetic patients also tend to rise after stopping Ozempic.

What Happens to Your Weight

The most extensively studied discontinuation scenario comes from the STEP 4 trial, published in JAMA in 2021. In this trial, 803 adults with Obesity received semaglutide 2.4 mg weekly for 20 weeks (achieving an average weight loss of ~10.6% of body weight), then were randomized to either continue semaglutide or switch to placebo for an additional 48 weeks.

Results at week 68 (48 weeks after randomization):

Continued semaglutide group: Lost an additional 7.9% of body weight (total ~18.5% from baseline)
Placebo (stopped semaglutide) group: Regained 6.9% of body weight — recovering approximately two-thirds of the weight lost during the initial 20 weeks

By the end of the trial, the gap between the two groups was approximately 14 percentage points of body weight. Patients who stopped semaglutide did not return to their exact starting weight within the trial period, but the trajectory was clearly toward full regain over a longer timeframe.

Why Weight Regain Happens

GLP-1 medications work by pharmacologically suppressing appetite and slowing gastric emptying. When the drug is removed, these effects disappear — typically within 1–2 weeks for semaglutide (which has a half-life of approximately 7 days). The underlying biological drivers of obesity — elevated appetite hormones, reduced satiety signaling, metabolic adaptations — reassert themselves.

This is analogous to stopping a blood pressure medication and watching blood pressure return to its pre-treatment level. Obesity is a chronic disease with a biological basis; GLP-1 drugs treat it pharmacologically, and stopping the treatment allows the disease to return.

There is also evidence that weight loss itself triggers compensatory hormonal changes (reduced leptin, increased ghrelin) that increase hunger and reduce energy expenditure — the so-called "metabolic adaptation" to weight loss. These adaptations persist after stopping GLP-1 drugs and contribute to regain.

What Happens to Blood Sugar (For Diabetes Patients)

For patients taking Ozempic or Mounjaro for type 2 diabetes, stopping the medication leads to a predictable rise in blood glucose and HbA1c. The magnitude depends on:

The patient's underlying diabetes severity
Whether other diabetes medications are being taken concurrently
Diet and exercise habits

In the SUSTAIN trials, patients who discontinued semaglutide for Type 2 Diabetes showed HbA1c returning toward baseline values within 12–16 weeks. Patients who were using semaglutide as their only diabetes medication (monotherapy) are at particular risk of glycemic deterioration after stopping.

Patients with type 2 diabetes should never stop Ozempic or Mounjaro without a plan for alternative glycemic management. This typically means transitioning to another diabetes medication (such as metformin, a DPP-4 inhibitor, or an SGLT2 inhibitor) before or at the time of discontinuation.

What Happens to Cardiovascular Risk Markers

GLP-1 medications have favorable effects on cardiovascular risk factors beyond weight and blood sugar:

Reduced blood pressure (typically 2–4 mmHg systolic)
Reduced triglycerides
Modest improvements in LDL and HDL cholesterol
Reduced inflammatory markers (CRP)

These effects are partially mediated by weight loss and partially by direct drug effects on the cardiovascular system. Stopping a GLP-1 drug will reverse the weight-loss-mediated improvements as weight is regained. The direct cardiovascular effects (such as blood pressure reduction independent of weight) also reverse after discontinuation.

For patients who were taking Wegovy specifically for cardiovascular risk reduction (the SELECT trial indication), stopping the drug removes a proven cardiovascular protective agent. This decision should be made in consultation with a cardiologist or primary care physician.

How Quickly Does Weight Come Back?

Weight regain after stopping GLP-1 drugs is not instantaneous. The typical pattern based on clinical trial data:

Timeframe After Stopping	Typical Weight Regain
1–4 weeks	Minimal; drug still clearing from system
1–3 months	Noticeable increase in appetite; 2–4% body weight regained
3–6 months	Accelerated regain; 5–8% body weight regained
6–12 months	Continued regain; approximately two-thirds of lost weight recovered
12–24 months	Most patients approach or reach original weight without intervention

The rate of regain varies significantly by individual. Patients who have made substantial lifestyle changes (diet quality, exercise habits, sleep, stress management) during their time on the medication tend to regain weight more slowly than those who relied primarily on the drug's appetite-suppressing effects.

Reasons Patients Stop GLP-1 Medications

Understanding why patients stop helps contextualize the regain risk:

Cost/insurance: The most common reason. Without insurance coverage, $900–$1,350/month is unsustainable for most patients. See the GLP-1 cost guide for savings strategies.

Side effects: Nausea, vomiting, and gastrointestinal discomfort cause approximately 5–10% of patients to discontinue in clinical trials. Most GI side effects improve significantly after the first 4–8 weeks of treatment.

Supply shortages: Ozempic and Wegovy have experienced significant supply disruptions. Patients forced to stop due to unavailability face the same regain risk as planned discontinuations.

Reached goal weight: Some patients and physicians plan a finite course of treatment. The evidence suggests this approach leads to regain unless lifestyle changes are exceptionally robust.

Pregnancy planning: GLP-1 drugs are not recommended during pregnancy. Patients planning to conceive should discuss timing with their physician.

Surgery: GLP-1 drugs should typically be held before procedures requiring anesthesia due to the risk of aspiration from delayed gastric emptying.

Strategies to Minimize Weight Regain

1. Dose Reduction Rather Than Abrupt Discontinuation

Some clinicians use a tapering approach — reducing from the maintenance dose (2.4 mg for Wegovy) to a lower dose (1 mg or 0.5 mg) before stopping entirely. This is not formally studied but is physiologically rational. The lower dose maintains some appetite suppression while reducing cost.

2. Transition to a Lower-Cost GLP-1

Older GLP-1 drugs like liraglutide (Victoza) or dulaglutide (Trulicity) are less expensive and may be more accessible for patients who cannot afford semaglutide or tirzepatide. They produce less weight loss but maintain some appetite suppression.

3. Intensify Lifestyle Interventions Before Stopping

Patients who use the period of GLP-1 treatment to establish durable dietary and exercise habits — rather than relying entirely on pharmacological appetite suppression — tend to maintain more weight loss after stopping. This includes:

Establishing a sustainable caloric deficit through food quality changes (not just quantity restriction)
Building an exercise habit that includes both resistance training and cardiovascular exercise
Addressing sleep quality and stress, both of which independently affect appetite hormones

4. Consider Maintenance Dosing

The STEP 5 trial demonstrated that semaglutide 2.4 mg maintained weight loss for 104 weeks (2 years) with continued treatment. For patients who can access and afford the medication, indefinite maintenance dosing is the most effective strategy — treating obesity as the chronic disease it is, analogous to indefinite statin therapy for hyperlipidemia.

5. Plan for Re-initiation

Patients who stop GLP-1 drugs due to temporary circumstances (surgery, pregnancy, supply shortage) should have a clear plan for re-initiation. Re-starting semaglutide after a gap requires re-titration from the lowest dose to minimize GI side effects.

The Bottom Line

Stopping Ozempic, Wegovy, or Mounjaro leads to predictable weight regain in most patients — approximately two-thirds of lost weight within one year, based on the best available trial data. This is a pharmacological reality, not a personal failure. GLP-1 medications treat obesity as a chronic disease, and like most chronic disease treatments, their benefits persist only with continued use.

For patients who must stop, the most effective mitigation strategies are dose tapering, transition to lower-cost alternatives, and intensive lifestyle intervention during the treatment period. For patients with type 2 diabetes, stopping without an alternative glycemic management plan is medically inadvisable.

For more on how GLP-1 drugs work, see How GLP-1 Medications Work. For a comparison of all available GLP-1 options, see the GLP-1 drug class guide.

Sources

Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. https://doi.org/10.1001/jama.2021.3224
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-2091. https://doi.org/10.1038/s41591-022-02026-4
Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604. https://doi.org/10.1056/NEJMoa1105816
FDA. Ozempic (semaglutide) Prescribing Information. Novo Nordisk, 2023.